Phase II - Mirdametinib

PreclinicalSmall molecule

Phase II - Mirdametinib is one of 72 small molecule programs targeting Lung Adenocarcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung AdenocarcinomaActive, not recruiting

Non-Small Cell Lung CancerRecruiting

Lung AdenocarcinomaPhase 1/Phase 2

Active, not recruiting

Non-Small Cell Lung CancerPreclinical

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Lenvima

Eisai

Preclinical

6 3

Imjudo

AstraZeneca

Preclinical

5 4

Vizimpro

Pfizer

Preclinical

4 5

Gilotrif

Boehringer Ingelheim

Preclinical

12 6

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 7

Treatment

GSK

Preclinical

1 8

Vidaza

Bristol-Myers Squibb

Preclinical

1 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Non-Small Cell Lung Cancer

NCT05937906

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Phase Ib/II Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.

Recruiting·CCentre Georges Francois Leclerc·Preclinical·NCT05937906·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Phase II - Mirdametinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Phase II - Mirdametinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Phase II - Mirdametinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Georges Francois Leclerc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCentre Georges Francois Leclerc

Phase II - Mirdametinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News